Robert Lorne Hopfner - Nov 7, 2025 Form 4 Insider Report for Evommune, Inc. (EVMN)

Role
Director, 10%+ Owner
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol
EVMN
Transactions as of
Nov 7, 2025
Transactions value $
$0
Form type
4
Date filed
11/12/2025, 04:19 PM
Previous filing
Nov 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopfner Robert Lorne Director, 10%+ Owner C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO /s/ Gregory S. Moss, Attorney-in-Fact 2025-11-12 0001551966

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVMN Common Stock Conversion of derivative security +3.03K 3.03K Nov 7, 2025 By Trust F1, F2
transaction EVMN Common Stock Conversion of derivative security +1.44M 1.44M Nov 7, 2025 By NFLS Delta III Limited F1, F3, F4, F5, F6
transaction EVMN Common Stock Conversion of derivative security +1.63M 1.63M Nov 7, 2025 By Pivotal bioVenture Partners Fund I, L.P. F1, F3, F4, F5, F7
transaction EVMN Common Stock Conversion of derivative security +295K 295K Nov 7, 2025 By Pivotal bioVenture Partners Fund II, L.P. F5, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVMN Series Seed Preferred Stock Conversion of derivative security -25.8K -100% 0 Nov 7, 2025 Common Stock 3.03K By Trust F1, F2
transaction EVMN Series Seed Preferred Stock Conversion of derivative security -7.15M -100% 0 Nov 7, 2025 Common Stock 839K By NFLS Delta III Limited F1, F6
transaction EVMN Series Seed Preferred Stock Conversion of derivative security -3.57M -100% 0 Nov 7, 2025 Common Stock 419K By Pivotal bioVenture Partners Fund I, L.P. F1, F7
transaction EVMN Series A Preferred Stock Conversion of derivative security -2.58M -100% 0 Nov 7, 2025 Common Stock 325K By NFLS Delta III Limited F3, F6
transaction EVMN Series A Preferred Stock Conversion of derivative security -7.23M -100% 0 Nov 7, 2025 Common Stock 909K By Pivotal bioVenture Partners Fund I, L.P. F3, F7
transaction EVMN Series B Preferred Stock Conversion of derivative security -1.9M -100% 0 Nov 7, 2025 Common Stock 241K By NFLS Delta III Limited F4, F6
transaction EVMN Series B Preferred Stock Conversion of derivative security -2.1M -100% 0 Nov 7, 2025 Common Stock 267K By Pivotal bioVenture Partners Fund I, L.P. F4, F7
transaction EVMN Series C Preferred Stock Conversion of derivative security -314K -100% 0 Nov 7, 2025 Common Stock 36.8K By NFLS Delta III Limited F5, F6
transaction EVMN Series C Preferred Stock Conversion of derivative security -314K -100% 0 Nov 7, 2025 Common Stock 36.8K By Pivotal bioVenture Partners Fund I, L.P. F5, F7
transaction EVMN Series C Preferred Stock Conversion of derivative security -2.51M -100% 0 Nov 7, 2025 Common Stock 295K By Pivotal bioVenture Partners Fund II, L.P. F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F2 The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F3 Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
F4 Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
F5 Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F6 Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F7 Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
F8 Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.